112 related articles for article (PubMed ID: 8647233)
41. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Triozzi PL; Tucker F; Benzies T; Balcerzak SP
Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
[TBL] [Abstract][Full Text] [Related]
42. Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).
Siena S; Bregni M; Bonsi L; Strippoli P; Peccatori F; Magni M; Di Nicola M; Bagnara GP; Massimo Gianni A
Stem Cells; 1993 Jul; 11 Suppl 2():72-5. PubMed ID: 8104618
[TBL] [Abstract][Full Text] [Related]
43. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
44. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
45. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
46. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
[TBL] [Abstract][Full Text] [Related]
47. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
48. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients.
Ross AA; Loudovaris M; Hazelton B; Weaver CH; Schwartzberg L; Bender JG
Exp Hematol; 1995 Dec; 23(14):1478-83. PubMed ID: 8542934
[TBL] [Abstract][Full Text] [Related]
49. Large volume leukapheresis following peripheral blood stem cell mobilization by cyclophosphamide and granulocyte-macrophage colony stimulating factor.
Safran H; Caguioa P; Tansan S
Prog Clin Biol Res; 1994; 389():639-42. PubMed ID: 7700930
[No Abstract] [Full Text] [Related]
50. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
[TBL] [Abstract][Full Text] [Related]
51. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer.
Stadtmauer EA; Hodi FS; Sickles C; Biggs DD; Mangan P; Buzby G; Zaleta E; Silberstein L
Prog Clin Biol Res; 1994; 389():487-95. PubMed ID: 7535458
[No Abstract] [Full Text] [Related]
52. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
[TBL] [Abstract][Full Text] [Related]
53. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
[TBL] [Abstract][Full Text] [Related]
54. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
[TBL] [Abstract][Full Text] [Related]
55. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
[TBL] [Abstract][Full Text] [Related]
56. Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies.
Chang Q; Hanks S; Akard L; Thompson J; Harvey K; English D; Jansen J
J Hematother; 1995 Aug; 4(4):289-97. PubMed ID: 7489143
[TBL] [Abstract][Full Text] [Related]
57. Variations in committed stem cells (CFU-GM and CFU-TL) in the peripheral blood of cancer patients treated by sequential combination chemotherapy for breast cancer.
Rusé-Riol F; Legros M; Bernard D; Chassagne J; Clavel H; Ferriere JP; Chollet P; Plagne R
Cancer Res; 1984 May; 44(5):2219-24. PubMed ID: 6713410
[TBL] [Abstract][Full Text] [Related]
58. The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.
Gheilmini M; Pettengell R; Coutinho LH; Testa N; Crowther D
Br J Haematol; 1996 Apr; 93(1):6-12. PubMed ID: 8611477
[TBL] [Abstract][Full Text] [Related]
59. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.
Elias AD; Mazanet R; Wheeler C; Anderson K; Ayash L; Schwartz G; Tepler I; Pap S; Pelaez J; Hunt M
Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S25-9. PubMed ID: 1687204
[TBL] [Abstract][Full Text] [Related]
60. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C; Hittelman WN; McAlister I; Garrison L; Williams DE
Blood; 1995 Sep; 86(6):2098-105. PubMed ID: 7662957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
